- Home
- TXO vs EYPT Comparison
TXO vs EYPT Comparison
Compare TXO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- EYPT
- Stock Information
- Founded
- TXO 2012
- EYPT 1987
- Country
- TXO United States
- EYPT United States
- Employees
- TXO N/A
- EYPT N/A
- Industry
- TXO Oil & Gas Production
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- TXO Energy
- EYPT Industrials
- Exchange
- TXO Nasdaq
- EYPT Nasdaq
- Market Cap
- TXO 788.9M
- EYPT 741.0M
- IPO Year
- TXO 2023
- EYPT 2005
- Fundamental
- Price
- TXO $14.10
- EYPT $11.61
- Analyst Decision
- TXO Strong Buy
- EYPT Strong Buy
- Analyst Count
- TXO 2
- EYPT 7
- Target Price
- TXO $22.50
- EYPT $24.29
- AVG Volume (30 Days)
- TXO 206.4K
- EYPT 702.4K
- Earning Date
- TXO 08-05-2025
- EYPT 08-06-2025
- Dividend Yield
- TXO 17.15%
- EYPT N/A
- EPS Growth
- TXO N/A
- EYPT N/A
- EPS
- TXO 0.30
- EYPT N/A
- Revenue
- TXO $332,267,000.00
- EYPT $51,898,000.00
- Revenue This Year
- TXO $31.08
- EYPT N/A
- Revenue Next Year
- TXO $11.32
- EYPT N/A
- P/E Ratio
- TXO $47.26
- EYPT N/A
- Revenue Growth
- TXO 15.94
- EYPT 2.99
- 52 Week Low
- TXO $13.35
- EYPT $3.91
- 52 Week High
- TXO $20.70
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- TXO 41.81
- EYPT 63.90
- Support Level
- TXO $13.85
- EYPT $10.84
- Resistance Level
- TXO $14.15
- EYPT $12.24
- Average True Range (ATR)
- TXO 0.33
- EYPT 0.59
- MACD
- TXO 0.01
- EYPT 0.06
- Stochastic Oscillator
- TXO 50.34
- EYPT 84.71
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.